Enzene Debuts NeX Partnership to Decentralize Biologics Production

The NeX program offers a turnkey model for governments and biopharma firms to establish domestic manufacturing capabilities. Instead of traditional, scale-intensive fed-batch layouts, the system relies on a compact, integrated architecture. According to CEO Himanshu Gadgil, this shift not only reduces capital requirements but also optimizes long-term yields, making life-saving treatments more affordable and accessible for regional patient populations.

Enzene handles the full lifecycle of these projects, from initial facility design and technology transfer to ongoing operational support. The initiative includes the SparX curriculum, designed to train local workforces in the specialized requirements of continuous manufacturing. Participants may also gain access to Enzene’s existing biosimilar portfolio. The company estimates that a facility can move from concept to commercial validation in under three years, providing a rapid route to building risk-mitigated supply chains.